Sickle Cell Disease Care Management and Treatment Continuing Education
Summary
S0844 revises Florida’s continuing education requirement for health care practitioners who are registered with the U.S. Drug Enforcement Administration and authorized to prescribe controlled substances. The bill keeps the existing 2-hour board-approved course requirement for biennial license renewal, but updates the course content to specifically include the treatment of pain for patients with sickle cell disease, alongside current standards for prescribing controlled substances, opioid alternatives, nonpharmacological therapies, emergency opioid antagonists, and the risks of opioid addiction during acute pain treatment.
The bill applies to prescribers across the state who must complete the course as part of licensure renewal, and it authorizes the course to be offered through distance learning. It also preserves the enforcement mechanism that prevents renewal of a prescriber’s license if the course is not completed, while maintaining the exemption for licensees whose practice acts already require at least 2 hours of controlled-substance prescribing education. The act takes effect July 1, 2026.
Impact
The bill amends section 456.0301, Florida Statutes, by expanding the required content of the statewide controlled-substance prescribing continuing education course. Its practical effect is to ensure that Florida prescribers receive instruction on sickle cell disease pain management as part of mandatory opioid and controlled-substance education, without changing the overall 2-hour requirement or the biennial renewal structure. It affects DEA-registered prescribers subject to Florida licensure renewal and reinforces the state’s licensing enforcement authority.
Sentiment
The bill appears to have broad bipartisan support and little visible opposition. It passed every recorded committee and floor vote unanimously in both chambers, including 11-0 in Senate Health Policy, 9-0 in Senate Appropriations Committee on Health and Human Services, 19-0 in Senate Fiscal Policy, 37-0 on Senate third reading, and 110-0 on House third reading. The unanimous votes suggest the measure was viewed favorably as a targeted education update rather than a controversial policy change.
Contention
No significant contention is reflected in the available record. The bill’s narrow focus on adding sickle cell disease pain treatment to an existing controlled-substance prescribing course likely limited disagreement. The only potentially notable policy issue is that the bill mandates specific educational content for prescribers, but the text and voting history show no recorded opposition from legislators or committees. The exemption for practitioners already required to complete comparable education also appears designed to reduce duplication concerns.